Archive

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year's EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: A new multiple myeloma classification system that correlates to disease stage and prognosis

Hans Erik Johnsen, Aalborg University Hospital, Denmark. by Maria Dalby:  The gene expression profiles of myeloma plasma cells in the normal bone marrow can be used for defining… read more.

EHA 2016: Smouldering Myeloma. Professor Maria-Victoria Mateos (Salamanca, Spain) discusses recent changes to the management of smouldering myeloma, her recommended work-up for these patients and the role of early treatment in this cohort.

EHA 2016: Molecular architecture of MM. Dr Brian Walker (University of Arkansas Medical School, Little Rock, USA) discusses his presentation in the education session on the molecular architecture of myeloma.

EHA 2016: What’s on the horizon in MM? Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) gives his take on what the future looks like for myeloma.

EuLITE: high cut-off haemodialysis doesn’t improve outcomes in myeloma cast nephropathy. Dr Mark Cook (University Hospitals Birmingham, UK) discusses the results of the EuLITE trial looking at free light chain removal by extended haemodialysis in cast nephropathy.

EHA 2016: Managing multiple myeloma in elderly/frail patients. Professor Antonio Palumbo (University of Torino, Italy) discusses the impact of age on outcomes (abstract E1295) and Professor Roman Hajek (University of Ostrava, Czech Republic) talks about preferred therapeutic strategies for elderly MM patients.

Managing multiple myeloma in elderly/frail patients   Although multiple myeloma is a disease of old age, elderly patients vary a great deal in terms of fitness and ability… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

EHA 2016: How monoclonal antibodies will change the treatment of multiple myeloma. Professor Antonio Palumbo (Torino, Italy) discuss the results of the CASTOR trial and Professor Meletios-Athanasios Dimopoulos (Athens, Greece) discussing POLLUX.

How monoclonal antibodies will change the treatment of multiple myeloma  by Maria Dalby   Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.

EMA Highlights: Green light for six new medicines

by Gary Finnegan: Six medicines, including two combination therapies for chronic hepatitis C, have been recommended for approval at the May meeting of the European Medicines Agency’s Committee for… read more.

ISH/BSH 2016 Abstracts and Posters: Results from the NCRI Myeloma XI trial

Charlotte Pawlyn and John R Jones (both of Institute of Cancer Research, London) and Ruth de Tute, St James’s University Hospital, Leeds. by Maria Dalby: Quadruplet therapy with… read more.

ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.